![Hospital_05](/var/esmo/storage/images/media/esmo-daily-reporter/images/aaa_generic-pictures-stock/hospital_patients/hospital_05/18862268-1-eng-GB/hospital_05_i770.jpg)
First gene engineered T-cell therapy for solid tumours confirmed to be a promising tool
The positive results of the SPEARHEAD-1 trial which showed durable responses of afamitresgene autoleucel in unresectable or metastatic synovial sarcoma granted FDA accelerated approval